Small and mid-cap biotech stocks entered 2025 like a compressed spring, and it finally snapped higher— here's why.

The NASDAQ Biotechnology Index (INDEXNASDAQ:NBI) is trading at three year highs despite market volatility, responding to ...

Hennion & Walsh CIO Kevin Mahn explains Morning Brief host Julie Hyman some of his investing outlooks for 2026, as he tries ...

XBI biotech ETF surged 65% as M&A heats up, but 2026 brings headwinds and tougher gains. Click here for a detailed analysis.

Detailed price information for Mainz Biomed N.V. (MYNZ-Q) from The Globe and Mail including charting and trades.

aTyr Pharma's leading candidate is targeting a relatively large market with unmet needs. The biotech company is expected to release data from a phase 3 clinical trial soon. Though things look somewhat ...

The ALPS Medical Breakthroughs ETF has staged a remarkable comeback, outperforming despite a challenging macro backdrop and small-cap weakness. SBIO benefited from a rebound in FDA drug approvals, ...

Biotech stocks have staged an impressive rally over the past six months, with the XBI index – key benchmark for small and mid ...

In the competitive world of small-cap biotechnology, CorMedix CRMD and Theravance Biopharma TBPH stand out as two companies working to turn scientific progress into lasting profits. Both companies, ...

Pulmonary sarcoidosis patients could soon get the treatment option they've been waiting for from aTyr Pharma. MoonLake Immunotherapeutics is running multiple phase 3 programs for its lead candidate.

The use of B-cell–depleting antibodies for autoimmune disease has been well validated with significant use of Roche Holdings AG (OTC:RHHBY) and Biogen Inc (NASDAQ:BIIB) partnered Rituxan (rituximab) ...